GLPG

Galapagos (GLPG)

About Galapagos (GLPG)

Galapagos NV is a biotechnology company, which engages in the identification and development of small molecule and antibody therapies. Its clinical pipeline includes filgotinib, GLP3667, Toledo program, and idiopathic pulmonary fibrosis. The company was founded by Onno van de Stolpe, Rudi Pauwels, and Helmuth van Es on June 30, 1999 and is headquartered in Mechelen, Belgium.

Details

Daily high

$31.35

Daily low

$30.72

Price at open

$31.14

52 Week High

$37.78

52 Week Low

$22.36

Market cap

2.1B

Dividend yield

0.00%

Volume

73,393

Avg. volume

91,473

P/E ratio

-4.18

Galapagos News